Standardization of plant extracts industry is significantly speeding up
April 18, 2012Chinese medicine extraction caused widespread concern in the industry. The 20 Chinese plants extracts trade standards drafting by the Chinese medicines and health products association has been completed. The pace of standardization of plant extracts industry in China is markedly accelerated.
China should develop the standard of the 500 kinds of commonly traditional Chinese plant extracts as soon as possible. The establishment of the Chinese herbal extract base to promote the development of traditional Chinese medicine extraction production to standardized, large-scale, modern. Skullcap, schisandra, echinacea, polygonum cuspidatum, wolfberry, mangosteen, blueberry, arrowroot, acanthopanax, heavy rain sheep hopane and other herb extracts, are currently exports more varieties. This is just one step of a comprehensive specification of Chinese herb extracts, and expand the variety of income set out to improve the international competitiveness of Chinese plant extract has a positive meaning.
In fact, in 2010, the Chinese plant extracts as a Chinese medicine second largest category of exports, total exports of $ 480 million, but under the impact of the export tax rebate adjustment in July, some varieties of exports declined year on year. Docetaxel extract other natural or reproduced by synthesis of glycosides and derivatives of this broad category, for example, annual exports amounting to $ 250 million. It is of 16.8 percent.
The other hand, the dietary supplement GMP Act introduced last year by the United States, Chinese herb extracts in China exported to the United States brought a certain extent. Japan and South Korea, Chinese herbal medicines, pesticide residues, heavy metals, sulfur dioxide and other WTO-TBT appraisal, implementation of new testing standards, a test of the extract of Chinese medicine business is not small. The draft has been the detection of pesticide residues, additional residual solvent testing items such as number of indicators included will also discuss the newly proposed standard to the heavy metal content.
From foreign technical barriers to break through traditional Chinese medicine extraction industry must quickly complied with international standards. The industry believes that Chinese herbal medicine extract industry is a lack of internal support. Extraction plant of traditional Chinese medicine irinotecan production enterprises set up mainly for internal production. The equipment is older with smaller scale production. It is difficult to form a scale. At the same time, because the extract preparation process characteristics, but also the extraction process equipment utilization is not high from the capital investment, a comprehensive measure of labor costs, energy consumption, poor economic returns, higher production costs.
A considerable number of Chinese enterprises are not built on the bases of Chinese herbal medicines. The transport costs are significantly high. In the production area of Chinese herbal origin, the production of plant extracts has a larger market. However, for the proposals of Chinese herbal medicines scale extraction, the researchers claim that it is still in conflict with the laws of China: At present, China has not yet regarded Chinese plant extracts as traditional medical raw materials. The statutory mandatory standard for Chinese medicine extracts does not come out.
Source:http://www.cospcn.com
Posted by tracy ma. Posted In : pharmaceutical raw materials